ABL1 (G250E)

ABL1 · Variant type: point · HGVS: p.G250E

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Nintedanib	100.0%	0.0%	90.23
2	Dasatinib	100.0%	0.0%	87.97
3	Bosutinib	100.0%	0.0%	87.22
4	Ponatinib	100.0%	0.0%	78.23
5	Axitinib	99.1%	0.9%	93.23
6	Vandetanib	99.0%	0.9%	95.74
7	Repotrectinib	98.5%	1.5%	84.21
8	Nilotinib	98.0%	2.0%	96.49
9	Brigatinib	97.6%	2.4%	82.96
10	Crizotinib	97.6%	2.4%	91.39
11	Canertinib	97.3%	2.7%	96.49
12	Pacritinib	95.2%	4.8%	88.64
13	Erdafitinib	93.2%	6.8%	95.71
14	Sunitinib	90.9%	9.1%	91.73
15	Fedratinib	89.8%	10.2%	96.21
16	Tivozanib	89.6%	10.4%	92.42
17	Dacomitinib	86.9%	13.1%	97.99
18	Afatinib	84.0%	16.0%	98.50
19	Erlotinib	83.0%	17.0%	99.75
20	Avapritinib	81.7%	18.3%	97.73
21	Gilteritinib	80.1%	19.9%	88.97
22	Entrectinib	80.0%	20.0%	93.69
23	Imatinib	75.0%	25.0%	99.00
24	Ripretinib	74.9%	25.1%	92.95
25	Selpercatinib	73.1%	26.9%	96.72

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Nintedanib	100.0%	99.9%	+0.1%
Dasatinib	100.0%	98.6%	+1.4%
Bosutinib	100.0%	99.7%	+0.3%
Ponatinib	100.0%	100.0%	+0.0%
Axitinib	99.1%	99.4%	-0.3%
Vandetanib	99.0%	95.7%	+3.3%
Repotrectinib	98.5%	93.6%	+5.0%
Nilotinib	98.0%	98.0%	+0.0%
Brigatinib	97.6%	82.8%	+14.8%
Crizotinib	97.6%	97.0%	+0.6%
Canertinib	97.3%	91.6%	+5.8%
Pacritinib	95.2%	92.0%	+3.2%
Erdafitinib	93.2%	90.9%	+2.2%
Sunitinib	90.9%	—	—
Fedratinib	89.8%	82.7%	+7.1%
Tivozanib	89.6%	95.8%	-6.2%
Dacomitinib	86.9%	80.8%	+6.1%
Afatinib	84.0%	—	—
Erlotinib	83.0%	—	—
Avapritinib	81.7%	—	—
Gilteritinib	80.1%	—	—
Entrectinib	80.0%	—	—
Imatinib	75.0%	86.2%	-11.2%
Ripretinib	74.9%	82.9%	-7.9%
Selpercatinib	73.1%	—	—

Cancer	Organ	Source
haematopoietic_neoplasm_haematopoietic_and_lymphoid_tissue	Blood/Lymphatic System	ref
lymphoid_neoplasm_haematopoietic_and_lymphoid_tissue	Blood/Lymphatic System	ref
carcinoma_lung	Lung	ref

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 15.3ms